The same unit does not make the medicines interchangeable
The letters “mg” tell you the unit used to express the amount of medicine. They do not tell you that equal amounts of two different drugs produce equal effects. Dividing one drug’s dose by the other drug’s dose gives an arithmetic ratio, not a clinical equivalence.
The Wegovy label describes semaglutide as a GLP-1 receptor agonist. The Zepbound label describes tirzepatide as acting at both GIP and GLP-1 receptors. Counting those targets does not supply a dose-conversion formula or predict your response.
A fictional comparison: “Is the bigger number too strong?”
Imagine Avery is discussing a change from semaglutide to tirzepatide. The proposed prescription has a larger milligram number. Avery worries that this means the new treatment is several times stronger and considers using only part of it.
The useful question is why the clinician chose that regimen for Avery’s history. Comparing the two printed numbers cannot answer it. Avery should clarify the prescription before using it, rather than resize a dose to make the numbers look similar. This example illustrates a misunderstanding; it does not suggest a starting dose or predict a treatment outcome.
Read switching instructions within their stated scope
Each product’s prescribing information has its own dosage section. The Wegovy label also contains instructions for certain switches between its injection and tablet forms. Those instructions concern specified Wegovy regimens; they are not instructions for changing from semaglutide to tirzepatide. See Wegovy sections 2.2–2.5.
An online chart may place two dose ladders side by side. Being on the same row does not establish equivalent treatment. Ask what evidence supports a proposed switch, which exact products it concerns and how your treatment experience affects the recommendation.
A comparison is not a reason to combine the medicines
The Zepbound prescribing information advises against use together with another tirzepatide-containing product or any GLP-1 receptor agonist. The Wegovy label similarly advises against use with other semaglutide products or other GLP-1 receptor agonists.
Do not alternate leftover medicines, overlap prescriptions or create a transition schedule from a comparison chart. Get clear instructions about the last dose of the old medicine and the first dose of the new one. Tell the prescriber if either date changes or if you have had a treatment gap.
Ask for the reasoning behind the new prescription
A useful explanation connects the proposed regimen to your circumstances. These prompts can keep the conversation focused on the decision:
- What problem are we trying to solve by changing medicines?
- How do my previous benefit, side effects and time off treatment affect this recommendation?
- What exactly should I use, when should I start it and which previous prescription ends?
- When will we assess the change, and whom should I contact if the instructions are unclear?
Use CoreAge Rx’s menu to identify the offer, then discuss the decision
CoreAge Rx’s product overview lists compounded semaglutide and tirzepatide. That menu identifies available categories; it does not establish which prescription fits you or make their dose numbers interchangeable. Its intake process describes a clinician evaluating medical history, medicines and allergies before approval or follow-up questions.
Compounded drugs are not FDA-approved. FDA recommends them only when an approved drug cannot meet the patient’s medical needs. Branded-product labeling does not establish approval or equal outcomes for a compounded offer. Use our personal-fit comparison and CoreAge Rx review to prepare questions about both the medicine and the service.
Common questions
Can I multiply my semaglutide dose to find a tirzepatide dose?
No. The two numbers are amounts of different medicines. Arithmetic alone does not establish an appropriate new prescription.
Does a lower milligram number mean fewer side effects?
Not when comparing different medicines. Ask about the actual product, regimen and your history; the smaller printed number is not a safety ranking.
Does this mean I can never switch?
A clinician may recommend changing treatment. The point is to obtain an individualized prescription and transition instructions rather than treat two dose numbers as equivalents.
Sources and fact-checking
Sources checked 2026-09-09. CoreAge Rx pages support descriptions of its service; medical and regulatory sources support the educational context. Offers and availability can change.